Roman Butler Fullerton & Co. Has $695,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Roman Butler Fullerton & Co. lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,567 shares of the pharmaceutical company’s stock after selling 83 shares during the quarter. Roman Butler Fullerton & Co.’s holdings in Vertex Pharmaceuticals were worth $695,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Banque Pictet & Cie SA increased its position in Vertex Pharmaceuticals by 7.0% in the 4th quarter. Banque Pictet & Cie SA now owns 12,043 shares of the pharmaceutical company’s stock valued at $4,850,000 after acquiring an additional 788 shares in the last quarter. V Square Quantitative Management LLC boosted its stake in shares of Vertex Pharmaceuticals by 13.2% in the 4th quarter. V Square Quantitative Management LLC now owns 4,186 shares of the pharmaceutical company’s stock valued at $1,686,000 after purchasing an additional 489 shares during the last quarter. First Merchants Corp boosted its stake in shares of Vertex Pharmaceuticals by 18.9% in the 4th quarter. First Merchants Corp now owns 592 shares of the pharmaceutical company’s stock valued at $238,000 after purchasing an additional 94 shares during the last quarter. Vontobel Holding Ltd. boosted its stake in shares of Vertex Pharmaceuticals by 66.8% in the 4th quarter. Vontobel Holding Ltd. now owns 188,949 shares of the pharmaceutical company’s stock valued at $76,090,000 after purchasing an additional 75,653 shares during the last quarter. Finally, Bogart Wealth LLC boosted its stake in shares of Vertex Pharmaceuticals by 15.8% in the 4th quarter. Bogart Wealth LLC now owns 22,259 shares of the pharmaceutical company’s stock valued at $8,964,000 after purchasing an additional 3,031 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on VRTX. Oppenheimer lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. UBS Group raised their target price on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $480.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday. Royal Bank of Canada lifted their price objective on shares of Vertex Pharmaceuticals from $402.00 to $407.00 and gave the stock a “sector perform” rating in a research note on Tuesday. Finally, Stifel Nicolaus lifted their price objective on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research note on Monday, December 16th. Ten investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $505.96.

Insider Buying and Selling

In related news, EVP Ourania Tatsis sold 310 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total transaction of $142,547.30. Following the transaction, the executive vice president now directly owns 64,021 shares in the company, valued at approximately $29,438,776.43. The trade was a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Stock Down 0.8 %

NASDAQ VRTX opened at $459.00 on Friday. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The firm’s 50 day moving average is $435.75 and its 200-day moving average is $461.80.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.94 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.